Mid- and small-cap medtechs find themselves at the mercy of government responses to the Covid-19 pandemic.
Success or failure on the stock markets this year depended almost entirely on whether a company’s devices could be used to treat coronavirus patients.
Chembio’s antibody test is the first to have its authorisation revoked. It might not be the last.
Medtronic’s newest closed-loop system posts decent pivotal data, but Insulet and Abbott are waiting in the wings.
The US is authorising new Covid-19 antibody tests faster than it is checking their accuracy.
Natera’s cancer blood test is couture, but Guardant’s pret-a-porter offering might sell better.
The German group has come late to antibody testing, but has punchy accuracy data and a possible means of neutralising some of the competition.
Liquid biopsy developer Grail exemplifies 2020’s trend of sizeable mid-stage financings.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.